Outcomes and Prognostic Factors in a Large Cohort of Hospitalized Cancer Patients With COVID-19.

Purpose: Patients with cancer are at increased risk for unfavorable outcomes from COVID-19. Knowledge about the outcome determinants of severe acute respiratory syndrome coronavirus 2 infection in this population is essential for risk stratification and definition of appropriate management. Our objective was to evaluate prognostic factors for all-cause mortality in patients diagnosed with both cancer and COVID-19.
Methods: All consecutive patients with cancer hospitalized at our institution with COVID-19 were included. Electronic medical records were reviewed for clinical and laboratory characteristics potentially associated with outcomes.
Results: Five hundred seventy-six consecutive patients with cancer and COVID-19 were included in the present study. An overall in-hospital mortality rate of 49.3% was demonstrated. Clinical factors associated with increased risk of death because of COVID-19 were age over 65 years, Eastern Cooperative Oncology Group performance status > 0 zero, best supportive care, primary lung cancer, and the presence of lung metastases. Laboratory findings associated with a higher risk of unfavorable outcomes were neutrophilia, lymphopenia, and elevated levels of D-dimer, creatinine, C-reactive protein, or AST.
Conclusion: A high mortality rate in patients with cancer who were diagnosed with COVID-19 was demonstrated in the present study, emphasizing the need for close surveillance in this group of patients, especially in those with unfavorable prognostic characteristics.
Competing Interests: Guilherme Nader MartaTravel, Accommodations, Expenses: Bayer Schering Pharma, Roche Renata Colombo BonadioResearch Funding: Novartis, AstraZenecaExpert Testimony: AcheTravel, Accommodations, Expenses: Roche, AstraZeneca Driele Peixoto BittencourtHonoraria: Novo Nordisk, EMS, GE Healthcare, NovartisConsulting or Advisory Role: Bayer Camilla Oliveira HoffLeadership: Rede D'OrStock and Other Ownership Interests: OncostarHonoraria: Bayer, Exelixis, Lilly, United MedicalConsulting or Advisory Role: Bayer, Exelixis, United Medical, LillyResearch Funding: Exelixis, Lilly Juliana PereiraConsulting or Advisory Role: AstraZeneca Vanderson RochaHonoraria: Takeda, Novartis, RocheConsulting or Advisory Role: Takeda, Agios, Zodiac Pharma, Novartis, AbbVieSpeakers' Bureau: Bristol Myers Squibb, Takeda, Amgen, Agios, Pfizer, Janssen Paulo M. HoffLeadership: Oncologia D'OrStock and Other Ownership Interests: OncoStar Oncology ClinicsHonoraria: Bayer Health, United MedicalConsulting or Advisory Role: United Health Group, Bayer, Lilly, ExelixisResearch Funding: Bayer, MSD Oncology, Novartis, Exelixis, Roche/Genentech, AstraZeneca/MedImmune, LillyNo other potential conflicts of interest were reported.